NEW YORK (GenomeWeb News) – Agendia today announced that insurer Humana will provide reimbursement for the firm's MammaPrint breast cancer recurrence test.
The Dutch molecular diagnostics firm said that the contract with Humana will expand coverage for MammaPrint by more than 17 million lives. Coding guidelines for the test were established in November 2009 by Palmetto GBA, California's Part B Medicare administrator.
The US Food and Drug Administration initially cleared the MammaPrint test in early 2007, making it the first in vitro diagnostic multivariate index assay device approved by the agency.
The firm performs the test at its CLIA-compliant labs in Amsterdam and Huntington Beach, Calif.